Drug Combination Details
| General Information of the Combination (ID: C93281) | |||||
|---|---|---|---|---|---|
| Name | Flavopiridol NP Info | + | Mitomycin C Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Stomach cancer
[ICD-11: 2B72]
|
Investigative | [1] | ||
|
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | MKN74 | CVCL_2791 | Gastric tubular adenocarcinoma | Homo sapiens | ||
| MDA-MB-468 | CVCL_0419 | Breast adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Flavopiridol potentiates the cytotoxic effect of the chemotherapeutic agent MMC by promoting drug-induced apoptosis in tumor cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res. 1997 Sep;3(9):1467-72. | |||
